Insider transactions

EDGAR

Tevogen Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
3 transactions, 972 shares
Sum of shares × price per share: 6,635.17

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–21 of 21

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-02 Filed 2026-11-04Saadi Ryan H. Director · Officer: Chief Executive Officer · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)50,000,0000—61,705,689Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Inc. (the Company) 2024 Omnibus Incentive Plan, which will vest only upon written certification by the Company's Board of Directors that the Company has achieved $1.0 billion in aggregate revenue during the period from November 2, 2026 through December 31, 2031 (the Performance Period). The shares will automatically be forfeited in the event such revenue threshold is not met during Performance Period, upon termination of the Reporting Person's service with the Company for any reason, if it is determined that the Reporting Person has engaged in certain misconduct or competitive activities with the Company, in the event of transfer or attempted transfer prior to vesting, or if the award is not assumed in connection with a change in control.
Open filing 0001493152-26-049968 Read from the filing’s XML Dispute this row
2026-09-14 Filed 2026-09-16Desai Kirti Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)750,0000—992,983Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Inc. (the Company) 2024 Omnibus Incentive Plan, which will vest only upon written certification by the Company's Board of Directors that the Company has achieved $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031 (the Performance Period). The shares will automatically be forfeited in the event such revenue threshold is not met during Performance Period, upon termination of the Reporting Person's service with the Company for any reason, if it is determined that the Reporting Person has engaged in certain misconduct or competitive activities with the Company, in the event of transfer or attempted transfer prior to vesting, or if the award is not assumed in connection with a change in control.
Open filing 0001123292-26-001312 Read from the filing’s XML Dispute this row
2026-09-14 Filed 2026-09-16Saadi Ryan H. Director · Officer: Chief Executive Officer · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)8,000,0000—11,705,689Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Inc. (the Company) 2024 Omnibus Incentive Plan, which will vest only upon written certification by the Company's Board of Directors that the Company has achieved $1.0 billion in aggregate revenue during the period from September 14, 2026 through September 30, 2031 (the Performance Period). The shares will automatically be forfeited in the event such revenue threshold is not met during Performance Period, upon termination of the Reporting Person's service with the Company for any reason, if it is determined that the Reporting Person has engaged in certain misconduct or competitive activities with the Company, in the event of transfer or attempted transfer prior to vesting, or if the award is not assumed in connection with a change in control.
Open filing 0001123292-26-001313 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Goh Keow Lin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)75,0000.00
0

Derived: shares × price per share. Exact value 0.00.

123,678Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.
Open filing 0001123292-26-001307 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15PODLOGAR SUSAN M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)75,0000.00
0

Derived: shares × price per share. Exact value 0.00.

123,678Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.
Open filing 0001123292-26-001306 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Sordillo Victor J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)75,0000.00
0

Derived: shares × price per share. Exact value 0.00.

126,539Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.
Open filing 0001123292-26-001305 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Feike Jeffrey L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)75,0000.00
0

Derived: shares × price per share. Exact value 0.00.

131,435Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.
Open filing 0001123292-26-001304 Read from the filing’s XML Dispute this row
2026-09-11 Filed 2026-09-15Patton Curtis L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)75,0000.00
0

Derived: shares × price per share. Exact value 0.00.

139,192Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.
Open filing 0001123292-26-001303 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Sordillo Victor J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)40,0000.00
0

Derived: shares × price per share. Exact value 0.00.

51,539Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.
Open filing 0001123292-26-000996 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10PODLOGAR SUSAN M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)40,0000.00
0

Derived: shares × price per share. Exact value 0.00.

48,678Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.
Open filing 0001123292-26-000994 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Feike Jeffrey L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)40,0000.00
0

Derived: shares × price per share. Exact value 0.00.

56,435Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.
Open filing 0001123292-26-000991 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Patton Curtis L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)40,0000.00
0

Derived: shares × price per share. Exact value 0.00.

64,192Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.
Open filing 0001123292-26-000993 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Desai Kirti Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)40,0000—242,983Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.
Open filing 0001123292-26-000990 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Goh Keow Lin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)40,0000.00
0

Derived: shares × price per share. Exact value 0.00.

48,678Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which vests in three equal installments upon the earlier of each of (i) the first anniversary of the grant date and the Issuer having aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date and the Issuer having aggregate revenue of $100 million since the grant date, and (ii) the third anniversary of the grant date and the Issuer having aggregate revenue of $150 million since the grant date, provided that the reporting person remains in service with the Issuer on the applicable vesting date.
Open filing 0001123292-26-000992 Read from the filing’s XML Dispute this row
2026-07-10 Filed 2026-07-10Saadi Ryan H. Director · Officer: Chief Executive Officer · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,220,0000—3,705,689Direct (D) No
F1
  • F1 Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which will vest ratably in four equal annual installments commencing on July 10, 2033, provided that the reporting person remains in service with the Issuer at such dates.
Open filing 0001123292-26-000995 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-03-17Flomenberg Neal Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5016.40
3,206.4

Derived: shares × price per share. Exact value 3206.40.

76,940Direct (D) No
F1, F2, F4
  • F1 The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person.
  • F2 The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
  • F4 These shares were sold in multiple transactions at prices ranging from $6.39 to $6.74, inclusive.
Open filing 0001123292-26-000465 Read from the filing’s XML Dispute this row
2026-03-11 Filed 2026-03-17Flomenberg Neal Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4527.26
3,281.52

Derived: shares × price per share. Exact value 3281.52.

77,441Direct (D) No
F1, F2, F3
  • F1 The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person.
  • F2 The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
  • F3 These shares were sold in multiple transactions at prices ranging from $7.25 to $7.33, inclusive.
Open filing 0001123292-26-000465 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-17Flomenberg Neal Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)197.75
147.25

Derived: shares × price per share. Exact value 147.25.

77,893Direct (D) No
F1
  • F1 The sales reported on this Form 4 were made solely to satisfy the payment of tax obligations relating to the vesting and subsequent settlement of restricted stock units. Such sales were not made at the discretion of the reporting person.
Open filing 0001123292-26-000465 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-22Saadi Ryan H. Director · Officer: Chief Executive Officer · 10% owner
G

Bona fide gift

Common Stock
Disposed (D)50,0000—124,284,453.322Direct (D) No
F1
  • F1 Represents a gift of 50,000 shares of common stock to Mount Bethel Volunteer Fire Company 1, which is a charitable entity.
Open filing 0001123292-25-000765 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-15Desai Kirti Officer: Chief Financial Officer
G

Bona fide gift

Common Stock
Disposed (D)300,0000—10,149,186Direct (D) No
F1
  • F1 Represents a gift of 100,000 shares of common stock to Shrimad Rajchandra Love and Care USA, Inc. and 200,000 shares of common stock to Shrimad Rajchandra Mission Dharampur (USA), Inc., which are charitable entities.
Open filing 0001123292-25-000757 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Saadi Ryan H. Director · Officer: Chief Executive Officer · 10% owner
G

Bona fide gift

Common Stock
Disposed (D)460,0000—124,334,453.322Direct (D) No
F1
  • F1 Represents a gift of 230,000 shares of common stock to each of Shrimad Rajchandra Love and Care USA, Inc. and Warren Township Honorary P.B.A., Inc., which are charitable entities.
Open filing 0001123292-25-000755 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–50 of 57

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager3,131,700 SH217,653 dollarsHigher by 2,104,309 Prior quarter: 1,027,391Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
FourWorld Capital Management LLC 1,450,000 SH9,599,000 dollarsUnchanged Prior quarter: 1,450,000Open filing 0001770525-26-000012 Filed 2026-11-16 Dispute this row
Calamos Advisors LLC 1,000,000 SH60,100 dollarsUnchanged Prior quarter: 1,000,000Open filing 0001316507-26-000004 Filed 2026-11-02 Dispute this row
Greenland Capital Management LP 703,029 SH42,252 dollarsUnchanged Prior quarter: 703,029Open filing 0001896430-26-000007 Filed 2026-11-16 Dispute this row
Polar Asset Management Partners Inc. 700,000 SH48,650 dollarsUnchanged Prior quarter: 700,000Open filing 0001326389-26-000099 Filed 2026-11-16 Dispute this row
MMCAP International Inc. SPC 650,000 SH45,175 dollarsUnchanged Prior quarter: 650,000Open filing 0000912282-26-001452 Filed 2026-11-12 Dispute this row
Linden Advisors LP 649,999 SH42,315 dollarsUnchanged Prior quarter: 649,999Open filing 0001193125-26-462390 Filed 2026-11-16 Dispute this row
HRT FINANCIAL LP 609,172 SH36 dollarsHigher by 445,263 Prior quarter: 163,909Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
Parallax Volatility Advisers, L.P. 300,000 SH18,030 dollarsLower by 490,917 Prior quarter: 790,917Open filing 0001172661-26-005336 Filed 2026-11-16 Dispute this row
Clear Street Group Inc. 282,806 SH19,655 dollarsUnchanged Prior quarter: 282,806Open filing 0001881567-26-000006 Filed 2026-11-16 Dispute this row
CANTOR FITZGERALD, L. P. Partly reported under another manager260,500 SH15,656 dollarsNot in the prior quarter’s filings read Open filing 0000929638-26-004323 Filed 2026-11-16 Dispute this row
Davidson Kempner Capital Management LP 250,000 SH17,375 dollarsUnchanged Prior quarter: 250,000Open filing 0001595082-26-000111 Filed 2026-11-16 Dispute this row
LMR Partners LLP Partly reported under another manager200,000 SH13,900 dollarsUnchanged Prior quarter: 200,000Open filing 0001578621-26-000193 Filed 2026-11-16 Dispute this row
Blue Owl Capital Holdings LP Partly reported under another manager200,000 SH12,000 dollarsUnchanged Prior quarter: 200,000Open filing 0001193125-26-459653 Filed 2026-11-13 Dispute this row
WOLVERINE ASSET MANAGEMENT LLC Partly reported under another manager199,638 SH13,875 dollarsLower by 1,000 Prior quarter: 200,638Open filing 0001279891-26-000016 Filed 2026-11-02 Dispute this row
O'Connor Alternative Investments, LLC 181,387 SH11,808 dollarsUnchanged Prior quarter: 181,387Open filing 0002081629-26-000010 Filed 2026-11-16 Dispute this row
Virtu Financial LLC Partly reported under another manager149,449 SH9 dollarsNot in the prior quarter’s filings read Open filing 0001533964-26-000015 Filed 2026-11-17 Dispute this row
Q Global Advisors, LLC 132,146 SH9 dollarsUnchanged Prior quarter: 132,146Open filing 0001469589-26-000019 Filed 2026-11-12 Dispute this row
TENOR CAPITAL MANAGEMENT COMPANY, L.P. 125,000 SH8,688 dollarsUnchanged Prior quarter: 125,000Open filing 0001346554-26-000092 Filed 2026-11-16 Dispute this row
Sculptor Capital LP Partly reported under another manager123,600 SH8,590 dollarsUnchanged Prior quarter: 123,600Open filing 0001193125-26-460943 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC Option: Call 115,000 SH7,992 dollarsUnchanged Prior quarter: 115,000Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
DRW Securities, LLC Partly reported under another manager100,000 SH6,950 dollarsUnchanged Prior quarter: 100,000Open filing 0001481986-26-000007 Filed 2026-11-13 Dispute this row
Westchester Capital Management, LLC Partly reported under another manager99,994 SH6,010 dollarsUnchanged Prior quarter: 99,994Open filing 0001512805-26-000013 Filed 2026-11-12 Dispute this row
Context Capital Management, LLC 97,250 SH6,759 dollarsUnchanged Prior quarter: 97,250Open filing 0001301396-26-000010 Filed 2026-11-04 Dispute this row
WHITEBOX ADVISORS LLC 86,292 SH5,997 dollarsUnchanged Prior quarter: 86,292Open filing 0001257391-26-000008 Filed 2026-11-16 Dispute this row
CITIGROUP INC Option: Call Partly reported under another manager77,151 SH4,637 dollarsUnchanged Prior quarter: 77,151Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
PICTON MAHONEY ASSET MANAGEMENT 75,000 SH5,212 dollarsUnchanged Prior quarter: 75,000Open filing 0001539041-26-000039 Filed 2026-11-09 Dispute this row
Yakira Capital Management, Inc. 65,128 SH4,526 dollarsUnchanged Prior quarter: 65,128Open filing 0001420506-26-002628 Filed 2026-11-13 Dispute this row
StoneX Group Inc. Partly reported under another manager37,238 SH1,811 dollarsHigher by 16,986 Prior quarter: 20,252Open filing 0000913760-26-000042 Filed 2026-11-03 Dispute this row
BOOTHBAY FUND MANAGEMENT, LLC 25,000 SH1,738 dollarsUnchanged Prior quarter: 25,000Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row
FLOW TRADERS U.S. LLC 17,649 SH1 dollarsUnchanged Prior quarter: 17,649Open filing 0001466697-26-000030 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 16,941 SH112,149 dollarsLower by 7,035 Prior quarter: 23,976Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager16,726 SH110,726 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
DUPONT CAPITAL MANAGEMENT CORP 12,500 SH751 dollarsUnchanged Prior quarter: 12,500Open filing 0001140361-26-040602 Filed 2026-10-23 Dispute this row
Bracebridge Capital, LLC 12,500 SH869 dollarsUnchanged Prior quarter: 12,500Open filing 0001426486-26-000007 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager11,619 SH76,917 dollarsNot in the prior quarter’s filings read Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
VANGUARD FIDUCIARY TRUST CO 7,515 SH49,749 dollarsHigher by 6,677 Prior quarter: 838Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager4,695 SH31,081 dollarsLower by 14,114 Prior quarter: 18,809Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager3,850 SH25,487 dollarsLower by 2,682 Prior quarter: 6,532Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
FMR LLC Partly reported under another manager831 SH5,501 dollarsLower by 8,995 Prior quarter: 9,826Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager154 SH1,000 dollarsUnchanged Prior quarter: 154Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager149 SH986 dollarsLower by 934 Prior quarter: 1,083Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager121 SH801 dollarsUnchanged Prior quarter: 121Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager112 SH756 dollarsLower by 281 Prior quarter: 393Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Arax Advisory Partners Partly reported under another manager33 SH218 dollarsLower by 368 Prior quarter: 401Open filing 0001586767-26-000009 Filed 2026-11-12 Dispute this row
FNY Investment Advisers, LLC 30 SH0 dollarsUnchanged Prior quarter: 30Open filing 0001742998-26-000005 Filed 2026-10-16 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager14 SH93 dollarsUnchanged Prior quarter: 14Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
Allworth Financial LP 10 SH67 dollarsLower by 40 Prior quarter: 50Open filing 0001140361-26-044466 Filed 2026-11-17 Dispute this row
IFP Advisors, Inc Partly reported under another manager7 SH46 dollarsLower by 22 Prior quarter: 29Open filing 0001641866-26-000005 Filed 2026-10-16 Dispute this row
Essential Partners LLC Partly reported under another manager4 SH26 dollarsLower by 13 Prior quarter: 17Open filing 0002136442-26-000010 Filed 2026-10-14 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • ARISTEIA CAPITAL, L.L.C. 245,176 SH
  • GOLDMAN SACHS GROUP INC 119,963 SH
  • TWO SIGMA SECURITIES, LLC 33,955 SH
  • AQR CAPITAL MANAGEMENT LLC 17,237 SH
  • JANE STREET GROUP, LLC 11,175 SH
  • Tower Research Capital LLC (TRC) 1,494 SH
  • GAMMA Investing LLC 762 SH
  • MERCER GLOBAL ADVISORS INC /ADV 572 SH
  • Integrated Wealth Concepts LLC 171 SH
  • NISA INVESTMENT ADVISORS, LLC 48 SH
  • BARCLAYS PLC 33 SH
  • Sterling Capital Management LLC 20 SH
  • Transamerica Financial Advisors, LLC 12 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Saadi Ryan H. Common Stock, par value $0.0001 per share91.161,709,567.0011/02/2026 Filed 2026-11-04SCHEDULE 13D/AAmendment 5Open filing 0001493152-26-049973 Dispute this row
Kirti Desai Common Stock, par value $0.0001 per share6.3992,98309/14/2026 Filed 2026-09-16SCHEDULE 13D/AAmendment 1Open filing 0001123292-26-001316 Dispute this row
Saadi Ryan H. Common Stock, par value $0.0001 per share74.411,709,56709/14/2026 Filed 2026-09-16SCHEDULE 13D/AAmendment 4Open filing 0001123292-26-001317 Dispute this row
Saadi Ryan H. Common Stock, par value $0.0001 per share59.73,709,56707/10/2026 Filed 2026-07-14SCHEDULE 13D/AAmendment 3Open filing 0001123292-26-001010 Dispute this row
Ryan H. Saadi Common Stock, par value $0.0001 per share62124,528,376.3212/11/2025 Filed 2025-12-16SCHEDULE 13D/AAmendment 2Open filing 0001123292-25-000761 Dispute this row
Ryan H. Saadi Common Stock, par value $0.0001 per share64.5125,008,376.3206/27/2025 Filed 2025-07-25SCHEDULE 13D/AAmendment 1Open filing 0001641172-25-021070 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,561,196 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020187,489
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to Tevogen Inc.